Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Patients With Metastatic Breast Cancer

NCT00191672 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00191672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00191672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Patients With Metastatic Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2003
Completion date
November 30, 2006
Enrollment
120
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms